[go: up one dir, main page]

CL2004000026A1 - Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino. - Google Patents

Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.

Info

Publication number
CL2004000026A1
CL2004000026A1 CL200400026A CL2004000026A CL2004000026A1 CL 2004000026 A1 CL2004000026 A1 CL 2004000026A1 CL 200400026 A CL200400026 A CL 200400026A CL 2004000026 A CL2004000026 A CL 2004000026A CL 2004000026 A1 CL2004000026 A1 CL 2004000026A1
Authority
CL
Chile
Prior art keywords
around
male
trans
clomifen
clomifene
Prior art date
Application number
CL200400026A
Other languages
English (en)
Inventor
Joseph Podolski
Original Assignee
Zonagen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23175972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2004000026(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zonagen Inc filed Critical Zonagen Inc
Publication of CL2004000026A1 publication Critical patent/CL2004000026A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

LA PRESENTE INVENCION SE REFIERE AL USO DE LAS COMPOSICIONES QUE CONTIENEN TRANS-CLOMIFENO PARA TRATAR A VARONES CON HIPOGONADISMO. LA INVENCION TAMBIEN SE REFIERE A LOS METODOS PARA TRATAR A VARONES CON HIPOGONADISMO.
CL200400026A 2001-07-09 2004-01-08 Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino. CL2004000026A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30431301P 2001-07-09 2001-07-09
PCT/US2002/021524 WO2003005954A2 (en) 2001-07-09 2002-07-09 Methods and materials for the treatment of testosterone deficiency in men

Publications (1)

Publication Number Publication Date
CL2004000026A1 true CL2004000026A1 (es) 2005-02-04

Family

ID=23175972

Family Applications (1)

Application Number Title Priority Date Filing Date
CL200400026A CL2004000026A1 (es) 2001-07-09 2004-01-08 Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.

Country Status (23)

Country Link
US (6) US7759360B2 (es)
EP (1) EP1411916B1 (es)
JP (2) JP4845165B2 (es)
KR (1) KR100851648B1 (es)
CN (2) CN1954807A (es)
AT (1) ATE406153T1 (es)
AU (1) AU2002318225B2 (es)
BR (1) BR0211067A (es)
CA (2) CA2453337C (es)
CL (1) CL2004000026A1 (es)
CO (1) CO5550428A2 (es)
CY (1) CY1108563T1 (es)
DE (1) DE60228583D1 (es)
DK (1) DK1411916T3 (es)
EC (1) ECSP044937A (es)
ES (1) ES2312593T3 (es)
MX (1) MXPA04000097A (es)
NZ (2) NZ530491A (es)
PL (1) PL211339B1 (es)
PT (1) PT1411916E (es)
RU (1) RU2297218C2 (es)
WO (1) WO2003005954A2 (es)
ZA (1) ZA200400142B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1411916T3 (da) 2001-07-09 2008-12-15 Repros Therapeutics Inc Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
US7737185B2 (en) 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
BRPI0513129A (pt) * 2004-07-14 2008-04-29 Repros Therapeutics Inc método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo
NZ556499A (en) * 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
JP5785680B2 (ja) * 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
WO2008157335A2 (en) 2007-06-13 2008-12-24 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US20090105348A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
CN102940619A (zh) 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US20090215733A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Therapy for the prophylaxis or treatment of adverse body composition changes and/or decreased muscle strength after androgen or gnrh analogue intake
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2474424C2 (ru) * 2010-09-24 2013-02-10 Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) * 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
ES2701400T3 (es) 2012-05-31 2019-02-22 Repros Therapeutics Inc Formulaciones para la administración vaginal de antiprogestinas
CA2880388A1 (en) 2012-08-21 2014-02-27 Repros Therapeutics Inc. Trans-clomiphene formulations and uses thereof
HK1211852A1 (en) 2012-11-02 2016-06-03 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
HK1216502A1 (zh) 2012-11-02 2016-11-18 Repros Therapeutics Inc. 用於癌症治療的反式-克羅米芬
US9814687B2 (en) * 2014-08-20 2017-11-14 Professional Compounding Centers Of America Transdermal pharmaceutical compositions including C-SERMs for low testosterone levels in men
RU2586305C1 (ru) * 2015-02-02 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения обструктивной азооспермии и криптозооспермии у пациентов с хроническим простатитом
CA2989364C (en) 2016-04-22 2021-07-20 F.I.S. - Fabbrica Italiana Sintetici S.P.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
EP0206021B1 (de) 1985-06-08 1988-08-10 ASTA Pharma AG Neue Derivate des 1,1,2,2-Tetramethyl-1,2-bis-(2-fluor-4-hydroxyphenyl)-ethans
US4820736A (en) 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) * 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5776923A (en) 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
AU2638795A (en) 1994-06-17 1996-01-15 University Of Nebraska Board Of Regents In situ gel-forming delivery vehicle for bio-affecting substances, and method of use
RU2089188C1 (ru) * 1994-07-13 1997-09-10 Владимир Александрович Божедомов Способ лечения мужского секреторного бесплодия
DE4435368A1 (de) 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
US6221399B1 (en) 1995-08-17 2001-04-24 Csir Method of making controlled release particles of complexed polymers
US5773031A (en) 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
DE69730982T2 (de) 1996-10-28 2005-09-01 General Mills, Inc., Minneapolis Einbettung und einkapselung von teilchen zur kontrollierten abgabe
NZ500649A (en) 1997-04-03 2001-05-25 Guilford Pharm Inc Biodegradable terephthalate polyester-poly(phosphate) polymers, compositions, articles, and methods for making a biosorbable suture, an orthopedic appliance or bone cement for repairing injuries to bone or connective tissue
US6653297B1 (en) 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
WO2000007996A2 (en) 1998-08-07 2000-02-17 Chiron Corporation Pyrazoles as estrogen receptor modulators
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
WO2000076522A1 (en) 1999-06-11 2000-12-21 Watson Pharmaceuticals, Inc. Administration of non-oral androgenic steroids to women
AU6132700A (en) 1999-09-30 2001-04-05 Chienna B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
US20020004065A1 (en) 2000-01-20 2002-01-10 David Kanios Compositions and methods to effect the release profile in the transdermal administration of active agents
WO2001091744A1 (en) 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
CN100448487C (zh) * 2000-08-11 2009-01-07 惠氏公司 治疗雌激素受体阳性癌的方法
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
AU2002213198A1 (en) 2000-10-11 2002-04-22 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
WO2002055020A2 (en) 2000-12-11 2002-07-18 Testocreme Llc Topical testosterone formulations and associated methods
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
DK1411916T3 (da) 2001-07-09 2008-12-15 Repros Therapeutics Inc Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
US6645974B2 (en) 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
AU2002330031B2 (en) 2001-09-21 2007-07-05 Merck & Co., Inc. Androstanes as androgen receptor modulators
US6600110B1 (en) * 2001-10-01 2003-07-29 Gram Precision Portable digital readout scale
US20060269611A1 (en) 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
BRPI0513129A (pt) 2004-07-14 2008-04-29 Repros Therapeutics Inc método de tratamento de condição selecionada do grupo que consiste em hipertrofia benigna de próstata, cáncer de próstata, trigliceridos elevados, colesterol alto e hipogonadismo
NZ556499A (en) 2005-02-04 2011-02-25 Repros Therapeutics Inc Methods and materials with trans-clomiphene for the treatment of male infertility
AU2006213856B2 (en) * 2005-02-11 2011-03-17 Regeneron Pharmaceuticals, Inc. Therapeutic combination of a VEGF antagonist (VEGF trap) and an anti-hypertensive agent
JP5785680B2 (ja) 2005-03-22 2015-09-30 リプロス セラピューティクス インコーポレイテッド トランス−クロミフェン用の投与レジメン
CA2617905A1 (en) 2005-08-05 2007-02-15 Repros Therapeutics Inc. Methods and compositions for treating female infertility using clomiphene
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
CN102940619A (zh) * 2007-10-16 2013-02-27 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US20100111901A1 (en) * 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TW201500041A (zh) 2008-11-07 2015-01-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) * 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
WO2013020215A1 (en) 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males

Also Published As

Publication number Publication date
RU2004100535A (ru) 2005-06-10
JP2005520779A (ja) 2005-07-14
US20040241224A1 (en) 2004-12-02
CO5550428A2 (es) 2005-08-31
PL211339B1 (pl) 2012-05-31
CN1954807A (zh) 2007-05-02
KR100851648B1 (ko) 2008-08-13
EP1411916A4 (en) 2005-08-17
DK1411916T3 (da) 2008-12-15
US20150265553A1 (en) 2015-09-24
US20140093560A1 (en) 2014-04-03
NZ551013A (en) 2008-04-30
ZA200400142B (en) 2006-02-22
CA2777199A1 (en) 2003-01-23
DE60228583D1 (de) 2008-10-09
KR20040013131A (ko) 2004-02-11
CA2453337C (en) 2012-08-28
CA2453337A1 (en) 2003-01-23
US20160354325A1 (en) 2016-12-08
EP1411916A2 (en) 2004-04-28
US7368480B2 (en) 2008-05-06
WO2003005954A3 (en) 2003-10-23
WO2003005954A2 (en) 2003-01-23
US7759360B2 (en) 2010-07-20
US20040097597A1 (en) 2004-05-20
ECSP044937A (es) 2004-04-28
WO2003005954B1 (en) 2003-12-04
US10561624B2 (en) 2020-02-18
ATE406153T1 (de) 2008-09-15
PT1411916E (pt) 2008-12-10
JP4845165B2 (ja) 2011-12-28
AU2002318225B2 (en) 2007-12-13
EP1411916B1 (en) 2008-08-27
US8618176B2 (en) 2013-12-31
CY1108563T1 (el) 2014-04-09
BR0211067A (pt) 2006-10-31
PL374121A1 (en) 2005-10-03
US20100286281A1 (en) 2010-11-11
JP2009280623A (ja) 2009-12-03
HK1071521A1 (en) 2005-07-22
CN1551765A (zh) 2004-12-01
MXPA04000097A (es) 2004-05-21
RU2297218C2 (ru) 2007-04-20
NZ530491A (en) 2007-08-31
ES2312593T3 (es) 2009-03-01
CN1289075C (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
CL2004000026A1 (es) Uso de una composicion que comprende 0 a alrededor de 29% de cis-clomifeno y de alrededor de 100 a alrededor de 71% de trans-clomifeno para preparar un medicamento util para aumentar los niveles de testosterona en suero en un mamifero masculino.
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
HN2001000146A (es) Derivados de pirazol
ES2157307T3 (es) Composicion topica que contiene un antagonista de sustancia p.
ATE281431T1 (de) Resorcin-derivate
ATE460939T1 (de) Verfahren zur behandlung von erektionsstörungen und steigerung der libido bei männern
ES2151277T3 (es) Composiciones que comprenden conjugados de acido cis-docosahexaenoico y taxotere.
ECSP034441A (es) Tratamiento de depositos de sulfuro de hierro
PA8564101A1 (es) Composiciones de goma de mascar y confiteria con composiciones de agente que elimina manchas encapsulado y procedimientos para su fabricacion y uso
GT199900102A (es) Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen.
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
ID26033A (id) Metode penstabilan komposisi bahan farmasi dengan penggunaan khusus dari antioksidan
AR020999A1 (es) Composiciones y proceso para la elaboracion de isotretinoina
TR200000110T2 (tr) Dezenfekte edici bileşimler ve yüzeyleri dezenfekte etme yöntemleri.
AU4584901A (en) Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
CY1105009T1 (el) Συνθεση καχαλαλιδης f
ES2176021T3 (es) Extracto de mirto, procedimiento de preparacion y aplicacion.
BR0009421A (pt) Inibidores de ligação lfa-1 aos icams e uso dos mesmos
BR0210101A (pt) Combinações antineoplásticas
ES2170143T3 (es) Composiciones que comprenden halofantrina en una forma especial.
AR030853A1 (es) Composicion plaguicida
ES2176920T3 (es) Composiciones para el tinte de las fibras queratinicas que contienen para-aminofenoles, procedimiento de tinte, nuevos para-aminofenoles y su procedimiento de preparacion.
BR9908114A (pt) Composições de gás de esterilização de óxido deetileno, pentafluoretano e heptafluorpropano
SG165144A1 (en) 1,2-substituted 2,3-dihydro-1h- 5,9-dioxacyclohepta[f]inden-7-ones and 7- substituted benzo[b][1,4]dioxepin-3-ones
DOP2001000150A (es) Agente hipertensivo y su uso